The Lynx Group
Cholangiocarcinoma News

Highlights from the 3rd Annual CCA Summit

New Frontiers in Surgery for CCA
Videos — January 14, 2022
Drs Alice Wei and Skye Mayo discuss options for induction therapy prior to surgery in iCCA.
Read More

Transplantation in iCCA
Videos — January 14, 2022
Drs Keri Lunsford and Maria Majella Doyle explore clinical data on neoadjuvant treatment before transplantation in patients with iCCA.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Potential therapeutic targets for cholangiocarcinoma (CCA) include oncogenic pathways and other options, such as epigenetics, posttranslational modifications, and metabolism, according to presentations delivered during Session I, “Advances in Translational/Molecular Targets in CCA: New Molecular Targets/Pathways in CCA,” at the 3rd Annual CCA Summit.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Cholangiocarcinoma (CCA) involves genetic heterogeneity, highlighting the need to identify new inherited variants, as discussed at the 3rd Annual CCA Summit in Session II, “Molecular Epidemiology of CCA.”
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Personalization of therapy and novel regimens are needed to improve options for patients with cholangiocarcinoma (CCA).
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Improved understanding of predictive biomarkers is needed in immuno-oncology, and various immunotherapy combinations using different mechanisms of action are being investigated in cholangiocarcinoma (CCA) and other biliary tract cancers, according to presentations delivered at Session IV, “What’s New in Immuno-­oncology in BTC? Monotherapy and Combo Therapies,” at the 3rd Annual CCA Summit.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
New biomarker technologies may be combined with cholangiocarcinoma (CCA) characteristics to predict patient response to treatment, according to presenters at Session V, “Biomarker Testing in CCA: New Technologies/­Imaging as a Biomarker,” during the 3rd Annual CCA Summit.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Dermatologic and ocular adverse events require appropriate and timely referral, and circulating tumor (ct) DNA analysis may not detect genomic fusions, as discussed in Session VI, “Molecularly Targeted Therapies in CCA,” at the 3rd Annual CCA Summit.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Mitesh J. Borad, MD, Mayo Clinic College of Medicine and Science, Phoenix, AZ, delivered an expert Keynote Perspective at the 3rd Annual Summit, highlighting genomic profiling as the standard of care in the management of patients with intrahepatic cholangio­carci­noma (CCA), with liquid biopsy becoming the tool of choice for geno­mic profiling in biliary tract cancers.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Rachna T. Shroff, MD, MS, University of Arizona Cancer Center, Tucson, delivered a Keynote Review at the 3rd Annual Summit of studies presented in several 2021 national and international meetings, highlighting advances in treatments targeting FGFR2, IDH1, and HER2 mutations and other alterations that led to recently approved new therapies. She reminded attendees that in 2021, 2 new targeted therapies have been approved by the FDA for patients with cholangiocarcinoma (CCA).
Read More

Page 1 of 3

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: